Dr. Cohen-Dayag explained, “Several years ago Compugen selected the field of immuno-oncology as its first focused discovery program, resulting in very successful immune checkpoint target discovery and validation efforts. We begin 2014 with multiple early-stage novel immune checkpoint candidates, in addition to the two that are the subject of a collaboration and license agreement signed last year. Moving forward, our increased oncology R&D budget is expected to allow us to advance more of these candidates in parallel, both for future additional early stage collaborations and our own internal development towards human clinical trials. Furthermore, since certain biomarkers, such as companion diagnostics, are expected to be highly beneficial in this rapidly growing field of immuno-oncology, we plan to establish a predictive biomarker discovery program for certain of our product candidates.”Dr. Cohen-Dayag concluded, “During 2014 we look forward to further demonstrating, both scientifically and commercially, the value of the unique and powerful predictive discovery infrastructure that has been created by Compugen, which we continue to enhance. Similar to last year, we expect to include in our 2013 yearend press release and conference call selected corporate objectives established for the current year.” About Compugen Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com. This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “potential,” “believes,” and “intends,” and describe opinions about future events. Forward-looking statements in this press release include, but are not limited to, statements regarding the expected increase during 2014 in the Company’s R&D activities and expenditures and the possible positive impact that such an increase could have on the number of Compugen’s immuno-oncology product candidates that could be advanced; the ability to establish a biomarker discovery program; the advancement of certain other discoveries and product candidates including targets for ADC use and the immunology arm of the Company’s Pipeline Program; and demonstration during the year of the scientific and commercial value of the Company’s discovery infrastructure. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks and other factors are discussed in the "Risk Factors" section of Compugen’s Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.